Werewolf Therapeutics, Inc. (HOWL) Stock Forecast
HOWL analyst forecast
as of October 18, 2026- Analyst consensus
- —
- Price target
- $7.00 average of analyst targets
- Upside to target
- +614.3% from the latest close
- Next earnings
- November 3, 2026 EPS estimate $-0.22
- 52-week range
- $0.31 – $1.77
HOWL price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
HOWL earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.22 | −$0.22 | −$0.22 | −$0.36 | +38.9% | 1 |
| Current fiscal year (2026) | −$0.89 | −$0.89 | −$0.89 | −$1.32 | +32.6% | 1 |
| Next fiscal year (2027) | −$0.59 | −$0.59 | −$0.59 | −$0.89 | +33.7% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
HOWL revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | — | — |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 2 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 2 |
HOWL EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
HOWL EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.22 | $0.00 | −$0.32 | −$0.32 | −$0.22 | 0.0% | 1 up · 0 down |
| Current fiscal year (2026) | −$0.89 | $0.00 | −$1.27 | −$1.27 | −$0.89 | 0.0% | 1 up · 0 down |
| Next fiscal year (2027) | −$0.99 | $0.00 | $0.00 | $0.00 | −$0.59 | −40.4% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
HOWL earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; HOWL beat in 9 of 12.
What analysts expect from HOWL
The average price target is $7.00, 614.3% above the latest close of $0.98. Analysts expect earnings of −$0.89 per share for 2026, +32.6% from a year earlier. For 2027 the average estimate is −$0.59 per share. Werewolf Therapeutics beat the EPS estimate in 9 of the last 12 quarters.
Related: HOWL income statement, HOWL key metrics, HOWL chart. See the HOWL stock overview for the latest quote and news.
HOWL forecast FAQ
What is Werewolf Therapeutics's price target?
The average analyst price target for Werewolf Therapeutics is $7.00, 614.3% above the latest close of $0.98.
What is Werewolf Therapeutics's EPS forecast?
Analysts forecast −$0.89 per share for 2026 (range −$0.89 to −$0.89); for 2027 the estimate is −$0.59.
When does Werewolf Therapeutics report earnings?
Werewolf Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 3, 2026; the EPS estimate is $-0.22.
Does Werewolf Therapeutics usually beat earnings estimates?
Werewolf Therapeutics reported EPS at or above the analyst estimate in 9 of the last 12 quarters.